Status:
NOT_YET_RECRUITING
The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)
Lead Sponsor:
Erasmus Medical Center
Conditions:
Frontal Fibrosing Alopecia
Cicatricial Alopecia
Eligibility:
All Genders
18+ years
Brief Summary
Frontal fibrosing alopecia (FFA) is a type of scarring hair loss that mostly affects women and causes permanent hair loss. Two medicines, hydroxychloroquine (HCQ) and methotrexate (MTX), are often use...
Detailed Description
Frontal fibrosing alopecia (FFA) is a form of primary cicatricial alopecia characterized by progressive, irreversible hair loss. It typically affects postmenopausal women. The disease presents with fr...
Eligibility Criteria
Inclusion
- Age 18 years or older
- Diagnosis of frontal fibrosing alopecia (FFA)
- Willing and able to provide written informed consent
- Adequate understanding of the Dutch language
- No known contraindications or allergies to hydroxychloroquine (HCQ) or methotrexate (MTX)
Exclusion
- Histopathological different diagnosis than FFA.
- Inability to adhere to the study protocol, including medication intake, clinic visits, and questionnaire completion.
- Patients who are ineligible for the HCQ arm (due to contraindications), are automatically included in the MTX arm.
- Contraindications HCQ: retinopathy and/or maculopathy/myasthenia gravis/body weight less than 35 kg
- \- Patients who are ineligible for the MTX arm (due to contraindications), are automatically included in the HCQ arm.
Key Trial Info
Start Date :
November 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT07190534
Start Date
November 1 2025
End Date
May 1 2027
Last Update
September 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus MC University Medical Center
Rotterdam, South Holland, Netherlands, 3015GD